コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 erall survival (OS) were estimated using the Kaplan-Meier method.
2 s, and survival curves were estimated by the Kaplan-Meier method.
3 val probabilities were computed by using the Kaplan-Meier method.
4 ting, and described time-to-report using the Kaplan-Meier method.
5 ee survivals (RFS) were calculated using the Kaplan-Meier method.
6 cer-specific survival were calculated by the Kaplan-Meier method.
7 recurrence survival was calculated using the Kaplan-Meier method.
8 We analyzed survival using the Kaplan-Meier method.
9 calculated from the time of RFA by using the Kaplan-Meier method.
10 Survival outcomes were estimated by the Kaplan-Meier method.
11 rmation-free, and overall survival) with the Kaplan-Meier method.
12 ysed data for response and survival with the Kaplan-Meier method.
13 sease-free survival were estimated using the Kaplan-Meier method.
14 erall survival (OS) were estimated using the Kaplan-Meier method.
15 -free survival analysis was assessed using a Kaplan-Meier method.
16 Survival was assessed using the Kaplan-Meier method.
17 PFS/DFS and OS were estimated by the Kaplan-Meier method.
18 in the 2 matched groups was analyzed by the Kaplan-Meier method.
19 OS rates were estimated using the Kaplan-Meier method.
20 -related mortality were calculated using the Kaplan-Meier method.
21 ed on the basis of TCNs and stage, using the Kaplan-Meier method.
22 on to seroreversion, was estimated using the Kaplan-Meier method.
23 Overall survival was calculated by the Kaplan-Meier method.
24 Event rates were estimated using the Kaplan-Meier method.
25 e-matched population was conducted using the Kaplan-Meier method.
26 DFS was calculated using the Kaplan-Meier method.
27 rvival (EFS) and OS were estimated using the Kaplan-Meier method.
28 and prognostic factors were tested with the Kaplan-Meier method.
29 Survival was calculated by using the Kaplan-Meier method.
30 or published results over time by using the Kaplan-Meier method.
31 ansplantation survival was assessed with the Kaplan-Meier method.
32 idelines, and survival was assessed with the Kaplan-Meier method.
33 inal discontinuation were assessed using the Kaplan-Meier method.
34 t-failure-free survival was estimated by the Kaplan-Meier method.
35 nontissue valves was compared by use of the Kaplan-Meier method.
36 Survival was determined using Kaplan-Meier method.
37 Overall survival was analyzed by using the Kaplan-Meier method.
38 lue of (18)F-FET PET was estimated using the Kaplan-Meier method.
39 continuation rates were calculated using the Kaplan-Meier method.
40 hose eligible for lifetime coverage with the Kaplan-Meier method.
41 Survival rates were assessed using the Kaplan-Meier method.
42 lative risks (CRs) were calculated using the Kaplan-Meier method.
43 ired t tests, and OS was calculated with the Kaplan-Meier method.
44 Time to mastectomy was estimated using the Kaplan-Meier method.
45 Three-year survival was estimated using the Kaplan-Meier method.
46 Fidelis lead survival was analyzed by the Kaplan-Meier method.
47 me-to-event analysis was performed using the Kaplan-Meier method.
48 progression-free survival were estimated by Kaplan-Meier method.
49 Survival was analyzed using Kaplan-Meier method.
50 t was overall survival (OS), assessed by the Kaplan-Meier method.
51 vival probabilities were estimated using the Kaplan-Meier method.
52 more than 30 days after resection using the Kaplan-Meier method.
53 Overall survival (OS) was estimated by the Kaplan-Meier method.
54 Survival was estimated using the Kaplan-Meier method.
55 ial rates of LR were calculated by using the Kaplan-Meier method.
56 rence probabilities were estimated using the Kaplan-Meier method.
57 ating complications were estimated using the Kaplan-Meier method.
58 verall survival (OS) was estimated using the Kaplan-Meier method.
59 ific (BCS) mortality were estimated with the Kaplan-Meier method.
60 erall survival also was comparable using the Kaplan-Meier method.
61 erall survival (OS) were estimated using the Kaplan-Meier method.
62 fidence intervals were computed by using the Kaplan-Meier method.
63 rence-free survivals were estimated with the Kaplan-Meier method.
64 (OS) survival rates were analyzed using the Kaplan-Meier method.
65 erall survival (OS) were conducted using the Kaplan-Meier method.
66 e risk estimates were obtained by use of the Kaplan-Meier method.
67 me-to-event curves were calculated using the Kaplan-Meier method.
68 etention time (DRT) were estimated using the Kaplan-Meier method.
69 CC recurrence incidence were compared by the Kaplan-Meier method.
70 Survival was analyzed by Kaplan-Meier method.
71 Survival data were obtained using the Kaplan-Meier method.
72 mortality estimates were estimated using the Kaplan-Meier method.
73 transplant survival was performed using the Kaplan-Meier method.
74 Survival was assessed by the Kaplan-Meier method.
75 outcome was overall survival (OS) using the Kaplan-Meier method.
76 Survival probabilities were based on the Kaplan-Meier method.
77 llograft survival was analyzed employing the Kaplan-Meier method.
78 Median survival was calculated by using the Kaplan-Meier method.
79 he overall survival rate was estimated using Kaplan-Meier method.
80 or progression-free survival outcomes by the Kaplan-Meier method.
81 Overall survival was calculated using the Kaplan-Meier method.
82 mined by Cox proportional hazards models and Kaplan-Meier method.
83 Survival rates were calculated using the Kaplan-Meier method.
84 reatment failures) was assessed by using the Kaplan-Meier method.
85 rimary end point was 6-month PFS assessed by Kaplan-Meier methods.
86 ulative incidence of PCO was estimated using Kaplan-Meier methods.
87 ates of discontinuation were estimated using Kaplan-Meier methods.
88 , class 2 obesity, and severe obesity) using Kaplan-Meier methods.
89 Survival and fBOS were estimated with Kaplan-Meier methods.
90 s test for correlated binary proportions and Kaplan-Meier methods.
91 Survival rates were estimated by using Kaplan-Meier methods.
92 The observed mortality was estimated using Kaplan-Meier methods.
93 Survival was computed using Kaplan-Meier methods.
94 p to 20 years of age was estimated by use of Kaplan-Meier methods.
95 progression-free survival was estimated with Kaplan-Meier methods.
96 nary revascularization) were calculated with Kaplan-Meier methods.
97 lly meaningful deterioration was analysed by Kaplan-Meier methods.
98 301 consecutive patients with ARVC using the Kaplan-Meier method adjusted to avoid the bias of delaye
101 by treatment cohort was estimated using the Kaplan-Meier method and analyzed using the log rank test
107 RFS and survival were estimated by using the Kaplan-Meier method and compared by using the log-rank t
108 We estimated risk of CRC over time by the Kaplan-Meier method and compared immigrants to controls
109 d overall survival (OS), estimated using the Kaplan-Meier method and compared using Cox models adjust
110 erall survival (OS) were described using the Kaplan-Meier method and compared using log-rank test.
111 tified as MET-high and -low was estimated by Kaplan-Meier method and compared using log-rank test.
113 OS) according to TRG were assessed using the Kaplan-Meier method and compared using the log-rank test
114 rall survival (OS) were determined using the Kaplan-Meier method and compared using the log-rank test
115 ifferent indications was estimated using the Kaplan-Meier method and compared using the log-rank test
116 ients matched by propensity scores using the Kaplan-Meier method and Cox models in "intention-to-trea
118 n-free survival (PFS) was analyzed using the Kaplan-Meier method and Cox proportional hazards modelin
119 between patients with and without RVAD using Kaplan-Meier method and Cox proportional hazards modelin
120 sion or recurrence) were evaluated using the Kaplan-Meier method and Cox proportional hazards modelin
121 ltivariate and stratified analysis using the Kaplan-Meier method and Cox proportional hazards models
122 g the first 5 years posttransplant using the Kaplan-Meier method and Cox proportional hazards models.
124 erall survival times were examined using the Kaplan-Meier method and Cox proportional hazards regress
131 pericarditis predicts cancer survival by the Kaplan-Meier method and Cox regression using a matched c
137 wn prognostic factors were calculated by the Kaplan-Meier method and evaluated with the log-rank test
141 Univariate analysis was performed with the Kaplan-Meier method and log-rank test, and multivariate
146 al after transplantation was estimated using Kaplan-Meier method and logistic regression to identify
149 [CS]) on PFS and OS were assessed using the Kaplan-Meier method and multivariable regression analysi
151 y blastoma and thyroid nodules), we used the Kaplan-Meier method and nonparametric cumulative inciden
157 rtality and as long-term mortality using the Kaplan-Meier method and using standardized mortality rat
158 erall survival (OS) rates were determined by Kaplan-Meier method and were compared by using the log-r
159 t were evaluated and calculated by using the Kaplan-Meier method and were compared by using the log-r
160 ival (PFS) rates were estimated by using the Kaplan-Meier method and were compared by using the one-s
161 3 years postoperatively was estimated using Kaplan-Meier methods and compared to the 5-year incidenc
162 lf-harm and risk factors for repetition with Kaplan-Meier methods and Cox proportional hazard models.
163 at, with the risk of events calculated using Kaplan-Meier methods and Cox proportional hazards analys
169 he risk of HIV infection was estimated using Kaplan-Meier methods and hazard ratios from proportional
171 cardiovascular mortality was compared using Kaplan-Meier methods and multivariable Cox proportional
172 r-specific survival were generated using the Kaplan-Meier method, and a Cox proportional hazards mode
174 e-free survival (DFS) were calculated by the Kaplan-Meier method, and a simplified QTNM score was dev
176 Survival outcomes were estimated by the Kaplan-Meier method, and Cox models were fit to determin
180 verall survival (OS) was estimated using the Kaplan-Meier method, and disease-specific survival (DSS)
181 Long-term survival was estimated by the Kaplan-Meier method, and independent predictors of morta
183 pairs signed-rank test, life-table analysis, Kaplan-Meier method, and log-rank test, as appropriate.
185 Survival estimates were calculated using the Kaplan-Meier method, and multivariable analysis was cond
186 tomy (RP), using descriptive statistics, the Kaplan-Meier method, and multivariable Cox proportional
187 Survival probability was calculated by the Kaplan-Meier method, and prognostic variables were analy
188 ward attainment were calculated by using the Kaplan-Meier method, and sex differences were assessed b
189 ival probabilities were calculated using the Kaplan-Meier method, and the association of covariates w
190 overall survival (OS) were estimated by the Kaplan-Meier method, and the association of HPV DNA dete
192 ong-term complications, determined using the Kaplan-Meier method, and the relation to mitomycin conce
195 FS and OS were estimated univariately by the Kaplan-Meier method, and treatment arms were compared by
196 ase-free survival (DFS) were estimated using Kaplan-Meier methods, and a multivariable Cox proportion
197 The risk of relapse was calculated using Kaplan-Meier methods, and predictors were determined usi
198 ar overall survival were estimated by use of Kaplan-Meier methods, and the 5-year cumulative incidenc
200 estimated the distribution of TFS using the Kaplan-Meier method, assessing between-group differences
203 fidence intervals (CIs) were estimated using Kaplan-Meier methods at 3, 12, and 36 months after treat
204 r transplantation was estimated by using the Kaplan-Meier method compared with log-rank tests and mod
205 Receiver operating characteristic curve, Kaplan-Meier method, Cox regression, and classification
206 P-free and survival rates were assessed with Kaplan-Meier method; differences between groups assessed
207 ll survival, TTP, and PFS were analyzed with Kaplan-Meier method; differences were compared with log-
211 1,568 recipients from 1987 to 2016 using the Kaplan-Meier method for time-to-event analysis and multi
213 Cumulative event rates were estimated by the Kaplan-Meier method; hazard ratios were calculated with
215 mpared with usual care, as determined by the Kaplan-Meier method (ICU survivor care 0.89 vs usual car
223 Overall survival was analyzed using the Kaplan-Meier method, log-rank test, Cox proportional haz
226 the unadjusted survival probabilities of the Kaplan-Meier method nor their adjustment for prognostic
227 ed survival analysis techniques, such as the Kaplan-Meier method, often are not appropriate for such
233 ssion to HG-IEN/BAc was calculated using the Kaplan-Meier method; the Cox regression model was used t
235 We used stepwise Cox regression and the Kaplan-Meier method to assess variables obtained at base
236 ts in the full analysis set predicted by the Kaplan-Meier method to be seizure-free at 6 months was 9
244 mor levels of EGFR with tumor stage, and the Kaplan-Meier method to estimate patients' median surviva
248 to first development of PDR was analyzed by Kaplan-Meier methods to calculate cumulative probabiliti
249 mpact on median overall survival (OS) by the Kaplan-Meier method, univariate analysis (log-rank test)
255 for competing risks was calculated; and the Kaplan-Meier method was used to analyze the importance o
256 ata were analyzed by intention to treat; the Kaplan-Meier method was used to assess 5-year event rate
270 ion probability at 7 years (estimated by the Kaplan-Meier method) was 10.5% (95% CI, 6.8% to 16.1%).
273 redicted by the nomogram and observed by the Kaplan-Meier method were similar at 3- and 5-year for pa
281 adjusted Cox proportional hazards models and Kaplan-Meier methods were used to estimate the effect of
285 cumulative incidence was estimated using the Kaplan-Meier method with age at onset as the time variab
286 calculated age-related penetrance using the Kaplan-Meier method with data for 603 individuals with t
287 state cancer survival was examined using the Kaplan-Meier method with deaths from other causes treate
288 eriod after the index prescription using the Kaplan-Meier method with log-rank test and stepwise regr
289 -to-event analyses were calculated using the Kaplan-Meier method with log-rank test for comparisons.
297 , long-term survival was evaluated using the Kaplan-Meier method, with comparisons based on the log-r
298 final discontinuation were assessed with the Kaplan-Meier method, with Cox proportional hazard models
299 ase-free survivals were determined using the Kaplan-Meier method, with differences determined by mult
300 Survival analyses were performed using the Kaplan-Meier method, with the differences in survival cu